Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT04302103 |
| Consolidated Lead Sponsor | RemeGen Co |
| Therapeutic Condition Cohort | Immunology, Rheumatology, and Dermatology |
| Clinical Trial Phase | Phase II |
| Overall Recruitment Status | COMPLETED |
| Registered Enrollment | 29 participants (ACTUAL) |
| Registered Start Date | 2020-07-07 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| Xiangya Hospital of Central South University | Changsha, China | Open Hospital Dossier -> |
| Jiangxi Provincial People's Hospital | Nanchang, China | Open Hospital Dossier -> |
| The First Hospital of Jilin University | Changchun, China | Open Hospital Dossier -> |
Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.